An Open, Single-arm, Single-centre Clinical Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours That Have Failed at Least One Prior Systemic Therapy
Latest Information Update: 14 Dec 2022
At a glance
- Drugs Cadonilimab (Primary) ; Regorafenib (Primary)
- Indications Biliary cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 14 Dec 2022 New trial record